Table A3.
The associations between the polymorphisms of CD44 and the cell differentiation status in lung adenocarcinoma.
| SNP Genotypes | All Cases (n = 279) | |||
|---|---|---|---|---|
| Well/Moderately-Differentiated (n = 247) | Poorly Cell Differentiated (n = 32) | AOR (95% CI) | p Value | |
| rs1425802 | ||||
| AA | 90 (36.4%) | 12 (37.5%) | 1.00 | |
| AG | 115 (46.6%) | 13 (40.6%) | 0.886 (0.379–2.071) | p = 0.779 |
| GG | 42 (17.0%) | 7 (21.9%) | 1.487 (0.526–4.204) | p = 0.455 |
| AG + GG | 157 (63.6%) | 20 (62.5%) | 1.029 (0.471–2.246) | p = 0.943 |
| rs187115 | ||||
| AA | 173 (70.0%) | 19 (59.4%) | 1.00 | |
| AG | 67 (27.1%) | 11 (34.4%) | 1.511 (0.671–3.402) | p = 0.319 |
| GG | 7 (2.9%) | 2 (6.2%) | 2.448 (0.450–13.325) | p = 0.300 |
| AG + GG | 74 (30.0%) | 13 (40.6%) | 1.605 (0.741–3.477) | p = 0.230 |
| rs713330 | ||||
| TT | 215 (87.0%) | 26 (81.3%) | 1.00 | |
| TC | 31 (12.6%) | 5 (15.6%) | 1.158 (0.400–3.347) | p = 0.787 |
| CC | 1 (0.4%) | 1 (3.1%) | 8.266 (0.425–160.676) | p = 0.163 |
| TC + CC | 32 (13.0%) | 6 (18.7%) | 1.371 (0.509–3.696) | p = 0.533 |
| rs11821102 | ||||
| GG | 220 (89.1%) | 27 (84.4%) | 1.00 | |
| GA | 23 (9.3%) | 5 (15.6%) | 2.048 (0.684–6.135) | p = 0.200 |
| AA | 4 (1.6%) | 0 (0%) | --- | --- |
| GA + AA | 27 (10.9%) | 5 (15.6%) | 1.677 (0.568–4.949) | p = 0.349 |
| rs10836347 | ||||
| CC | 209 (84.6%) | 28 (87.5%) | 1.00 | |
| CT | 37 (15.0%) | 4 (12.5%) | 0.854 (0.278–2.630) | p = 0.784 |
| TT | 1 (0.4%) | 0 (0%) | ---- | --- |
| CT + TT | 38 (15.4%) | 4 (12.5%) | 0.843 (0.274–2.594) | p = 0.766 |
| rs13347 | ||||
| CC | 106 (42.9%) | 17 (53.1%) | 1.00 | |
| CT | 123 (49.8%) | 13 (40.6%) | 0.565 (0.256–1.248) | p = 0.158 |
| TT | 18 (7.3%) | 2 (6.3%) | 0.586 (0.121–2.848) | p = 0.508 |
| CT + TT | 141 (57.1%) | 15 (46.9%) | 0.567 (0.264–1.218) | p = 0.146 |
The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age and gender. Abbreviations: SNP, single nucleotide polymorphism; AOR, adjusted odds ratio; CI, confidence interval.